PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX 100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at